Embecta : Analyst & Investor Day Presentation (5d3437)

Published: 2025-05-22 09:04:29 ET EMBC

Published on 05/22/2025 at 09:04

May 22, 2025

1

New York, New York

Pravesh Khandelwal

Vice President, Investor Relations

2

2

Safe Harbor Statement Regarding Forward-Looking Statements

This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding our future results from operations, performance, financial condition, goals, strategies, plans and achievements. These forward-looking statements are subject to various known and unknown risks, uncertainties and other factors, and you should not rely upon them except as statements of our present intentions and of our present expectations, which may or may not occur. When we use words such as "believes," "may," "might," "could," "predict," "seek," "look," "next," "project," "potential," "continue," "expand," "objective," "grow," "goal," "expects," "anticipates," "estimates," "plans," "intends," "pursue," "should," "would," "will," "target," "create," "opportunity," "capability," "position," "strategy," or similar expressions, we are making forward-looking statements. For example, embecta is using forward-looking statements when discussing our future operations and financial performance and statements regarding our business strategy, key market and portfolio expectations, U.S. and International business and strategy, manufacturing and supply chain expectations, execution of our brand transition plan, expectations for value creation, our financial profile and long-term financial objectives, including our fiscal 2025 financial guidance and over the course of our long-range plan, expectations related to the impact of incremental tariffs, our plans to discontinue our patch pump program, increasing our financial flexibility and our ability to reduce costs, streamline operations and enhance profitability, our expected savings and expenses from our organizational restructuring and the timing thereof, our expectations with respect to strengthening our core business, separating and standing up embecta as an independent company, expansion of our product portfolio, and opportunities to transition into a broad-based medical supplies company. Although we believe that our forward-looking statements are based on reasonable assumptions, our expected results may not be achieved, and actual results may differ materially from our expectations. In addition, important factors that could cause actual results to differ from expectations include, among others: (i) competitive factors that could adversely affect embecta's operations; (ii) any inability to replace the services provided by Becton, Dickinson and Company ("BD") under the transaction documents; (iii) any failure by BD to perform its obligations under the various separation agreements entered into in connection with the separation and distribution; (iv) any events that adversely affect the sale or profitability of embecta's products or the revenues delivered from sales to its customers; (v) increases in operating costs, including costs incurred from newly instituted tariffs by the U.S. government and certain foreign governments on raw materials and products, fluctuations in the cost and availability of raw materials or components used in embecta's products, the ability to maintain favorable supplier arrangements and relationships, and the potential adverse effects of any disruption in the availability of such items; (vi) the impact of the global trade environment resulting from newly instituted tariffs causing certain foreign governments, private purchasers and others to consider transitioning away from products originating from certain countries (including the U.S.) in favor of buying "local" products; (vii) changes in reimbursement practices of governments or private payers or other cost containment measures; (viii) the adverse financial impact resulting from unfavorable changes in foreign currency exchange rates, as well as regional, national and foreign economic factors, including inflation, deflation, and fluctuations in interest rates; (ix) the impact of changes in U.S. federal laws and policy that could affect fiscal and tax policies, healthcare and international trade, including import and export regulation and international trade agreements;

(x) any new pandemic or any geopolitical instability, including disruptions in its operations and supply chains; (xi) new or changing laws and regulations, or changes in enforcement practices, including laws relating to healthcare, environmental protection, trade, monetary and fiscal policies, taxation and licensing and regulatory requirements for products; (xii) the expected benefits of the separation from BD; (xiii) risks associated with embecta's indebtedness; (xiv) the risk that ongoing dis-synergy costs, costs of restructuring and other costs incurred in connection with the separation from BD will exceed our estimates of these costs; (xv) the risk that it will be more difficult than expected to effect embecta's full separation from BD; (xvi) the risks related to timely and successfully completing the brand transition, including any resulting regulatory registration and license delays and interruptions in the transition of the rebranded products into commercial operations, networks, administrative operations and end-to-end product flow and user access; (xvii) expectations related to the costs, profitability, timing and the estimated financial impact of, and charges and savings associated with, the restructuring plans we announced; (xviii) risks associated with not completing strategic collaborative partnerships and acquisitions for innovative technologies, complementary product lines, and new markets; and (xix) the other risks described in our periodic reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors" in our most recent Annual Report on Form 10-K, as further updated by our Quarterly Reports on Form 10-Q we have filed or will file hereafter. Except as required by law, we undertake no obligation to update any forward-looking statements appearing in this presentation.

3

Market trends and portfolio highlights

U.S. business and strategy

International business and strategy

Manufacturing and supply chain overview

Q&A session

Value creation opportunities

Financial overview

Q&A session

Agenda

4

Track record of best-in-class execution through challenging environments

Dev Kurdikar Chief Executive Officer

Jake Elguicze Chief Financial Officer

Ginny Blocki

SVP, Strategy

Tom Blount SVP, President, North America

5

Slobodan Radumilo SVP, President, International

Shaun Curtis

SVP, Manufacturing, Supply Chain and Quality

Jeff Mann

GC and Head of Product Development

Jean Casner Chief Human Resources Officer

Disclaimer

Embecta Corporation published this content on May 22, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 22, 2025 at 13:03 UTC.